Effect of moxidectin in treatment of scabies
Phase 2
- Conditions
- patients diagnosed of having scabies.Scabies
- Registration Number
- IRCT20191030045275N1
- Lead Sponsor
- Faculty of Medicine, Tanta University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
(A) Clinical: 1. Intense pruritus especially at night. 2. Typical distribution of the excoriated papulovesicular lesions; around umbilicus, flexures, genitalia, interdigital spaces. 3. Affection of other family members.
(B) Parasitological: By detection of Sarcoptes Scabeii mites (adult, larvae and eggs) in cutaneous scrapings.
Exclusion Criteria
Patients with recent topical or systemic treatments of scabies.
Patients with clinical bacterial infection or any other associated skin disease.
Patients with any evident systemic diseases causing pruritus.
Pregnant and lactating women.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical lesions and degree of pruritus. Timepoint: 1 week after intervention. Method of measurement: Clinical evaluation.;Mites count. Timepoint: 1 week after intervention. Method of measurement: Microscopic examination of mites.
- Secondary Outcome Measures
Name Time Method